Basel, Switzerland (PRWEB) December 03, 2013
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced its successful collaboration with AstraZeneca on data analysis for compound combination experiments. Drug combination studies, which are increasingly used in pre-clinical research, produce large volumes of data with upwards to 200 combinations per experiment. Genedata Screener, which has been proven to work as an easy and efficient platform for analyzing compound screening, has been advanced through the AstraZeneca collaboration as Genedata Screener now automates and standardizes the analysis of compound combination experiments.
“With Genedata, we are able to extract the highest value possible from our compound combination experiments,” noted Dr. Eric Tang, associate principle scientist at AstraZeneca. “Typically, compound combination experiments compare 50 or more compounds across a number of cell lines in a single study, resulting in the analysis of hundreds of 384/1536 well plates. Genedata Screener can handle these large data sets and enable us to generate and compare results for the same compound combinations in different cell lines, and review alternative analysis for the same data sets. Moreover, Screener helps standardize data analysis giving us more quality time to conduct detailed analysis,” continued Dr. Tang.
From Raw Data to Synergy Scores in Minutes
Combination therapies – the simultaneous use of a variety of drugs to treat a range of diseases from infections to cancer – have gained importance as a cure. And, compound combination experiments are a resurging trend in lead optimization and target validation. Data sets from these experiments tend to be large, as the number of measurements scales exponentially with the number of compounds to be compared. Genedata Screener effectively addresses the data analysis challenges of these large data sets by enabling researchers to:
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.